|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Medical College of Wisconsin |
|---|---|
| Information provided by: | Medical College of Wisconsin |
| ClinicalTrials.gov Identifier: | NCT00846092 |
Purpose
Summary of Study Rationale Near-infrared light (NIR) via light-emitting diodes (LED) treatment promotes retinal healing and improve visual function following high intensity laser retinal injury by augmenting cellular energy metabolism, enhances mitochondrial function, increases cytochrome C oxidase activity, stimulates antioxidant protective pathways, and promotes cell survival. LED directly benefits injured neurons in the retina, the lateral geniculate nucleus, and the visual cortex, where perception occurs. From a public health perspective, a Light-Emitting Diode (LED) Array study is important to conduct because it has been approved as a non-significant risk (NSR) device for treatment of eye disorders, it has a low cost of treatment, and it may serve as an effective, non-invasive alternative or adjunctive treatment to laser photocoagulation, the current standard of care for DME.
Study Objectives and Hypotheses
| Condition | Intervention | Phase |
|---|---|---|
|
Diabetic Macular Edema |
Device: Warp 10 LED Device Device: Near-infrared light (NIR) |
Phase I |
| Study Type: | Interventional |
| Study Design: | Allocation: Non-Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | Phase 1 Study To Determine the Effects of Short Term Near-infrared Light (NIR) Therapy on Anatomic and Functional Abnormalities of Diabetic Macular Edema, and Assess Safety of Short Term Near-infrared Light Therapy in Eyes With Diabetic Macular Edema. |
| Estimated Enrollment: | 20 |
| Study Start Date: | November 2007 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | September 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
Experimental: Device
Primary efficacy and toxicity outcomes are determined by measuring excess retinal thickness via Ocular Coherence Tomography at 1 month, 3 months, and 6 months, prior to conclusion of the study. • This protocol will be stopped if, at any point in the study, a 50% increase in excess retinal thickness is demonstrated via OCT in 25% of subjects in the experimental group. |
Device: Warp 10 LED Device
Study Subjects will take the Warp 10 (LED) home and treat twice per day for three months
Other Name: Warp 10
Device: Near-infrared light (NIR)
Other Name: Warp 10 LED's
|
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Diagnosis of diabetes mellitus (type 1 or type 2)
• Any one of the following will be considered to be sufficient evidence that diabetes is present: Current regular use of insulin for the treatment of diabetes Current regular use of oral anti-hyperglycemia agents for the treatment of diabetes Documented diabetes by ADA and/or WHO criteria (see Procedures Manual for definitions)
Any candidate identified by a study investigator as being able to successfully tolerate a 3 month deferral of laser photocoagulation.
Exclusion Criteria:
Participation in an investigational trial within 30 days of NIR participation that involved treatment with any drug that has not received regulatory approval at the time of study entry.
• Note: subjects cannot receive another investigational drug while participating in the study during the first 6 months...
Major surgery within 28 days prior to participation or major surgery planned during the next 6 months.
• Major surgery is defined as a surgical procedure that is more extensive than fine needle biopsy/aspiration, placement of a central venous access device, removal/biopsy of a skin lesion, or placement of a peripheral venous catheter.
Contacts and Locations| Contact: Harry T Whelan, MD | 414-266-7544 | hwhelan@mcw.edu |
| Contact: Dennis P Han, MD | 414-456-2020 | dhan@mcw.edu |
| United States, Wisconsin | |
| Medical College of Wisconsin | Recruiting |
| Milwaukee, Wisconsin, United States, 53226 | |
| Contact: Harry T Whelan, MD 414-266-7544 hwhelan@mcw.edu | |
| Contact: Dennis P Han, MD 414-456-2020 dhan@mcw.edu | |
| Principal Investigator: Harry T Whelan, MD | |
| Sub-Investigator: Dennis P Han, MD | |
| Principal Investigator: | Harry T Whelan, MD | Medical College of Wisconsin |
More Information
| Responsible Party: | Harry T. Whelan, M.D., Medical College of Wisconsin |
| ClinicalTrials.gov Identifier: | NCT00846092 History of Changes |
| Other Study ID Numbers: | NIR for Diabetic Maculopathy |
| Study First Received: | February 16, 2009 |
| Last Updated: | August 10, 2010 |
| Health Authority: | United States: Institutional Review Board |
|
Diabetic Retinopathy Diabetic Macular Edema NIR Near-infrared Light Therapy |
|
Edema Macular Edema Signs and Symptoms Macular Degeneration |
Retinal Degeneration Retinal Diseases Eye Diseases |